|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Assistance Publique Hopitaux De Marseille |
|---|---|
| Information provided by: | Assistance Publique Hopitaux De Marseille |
| ClinicalTrials.gov Identifier: | NCT00920335 |
Purpose
Adult intracranial ependymoma is a relatively rare brain tumour entity, accounting for 2-5% of all intracranial neoplasms. The pertinent prognostic factors as well as the pattern of recurrence remain to be elucidated. According to several recent reports, the prognostic value of Karnofski performance status, tumour location, the extent of surgical removal, histological grade and even postoperative radiotherapy remain controversial. As a consequence, optimal therapeutic management of adult intracranial ependymomas remains an ongoing debate. For this reason, a retrospective study conducted by the French society of neurosurgery (SFNC), neuropathology (SFNP) and the association of the neuro-oncologists of French expression (ANOCEF) was undertaken and allowed to collect 258 cases coming from 25 centers, initially diagnosed as intracranial ependymomas between 1990 and 2004. Clinical and follow-up data of these patients are known and the paraffin embedded samples as well as the frozen tissues available have been centralized. Central pathological review of these 258 cases was conducted by two senior neuropathologists and confirmed the diagnosis of ependymoma in 152 cases, thus constituting the most important series of the literature. Few molecular studies were carried out on ependymomas. The investigators have the opportunity, based on this important series, to determine the clinicopathological criteria and the molecular markers who will allow a better characterization of the diagnosis and the prognosis of these tumors.
| Condition | Intervention |
|---|---|
|
Intracranial Ependymoma |
Other: tumoral sample |
| Study Type: | Interventional |
| Study Design: | Diagnostic, Open Label, Single Group Assignment |
| Official Title: | Adult Intracranial Ependydomas : Prognostic and Diagnostic Factors Assessment and Molecular Characterization |
| Estimated Enrollment: | 192 |
| Study Start Date: | March 2009 |
| Estimated Primary Completion Date: | April 2012 (Final data collection date for primary outcome measure) |
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Contact: philippe METELLUS | philippe.metellus@ap-hm.fr |
| France | |
| Assistance Publique Hopitaux De Marseille | Recruiting |
| MARSEILLE, France | |
| Contact: PHILIPPE METELLUS | |
| Principal Investigator: PHILIPPE METELLUS | |
| Principal Investigator: | philippe METELLUS | Assistance Publique Hopitaux De Marseille |
More Information
| Responsible Party: | Direction de la recherche ( Assistance Publique Hopitaux De Marseille ) |
| Study ID Numbers: | 2008-25, 2008-A01289-46 |
| Study First Received: | May 4, 2009 |
| Last Updated: | August 3, 2009 |
| ClinicalTrials.gov Identifier: | NCT00920335 History of Changes |
| Health Authority: | France: Afssaps - French Health Products Safety Agency |
|
Adult intracranial ependymoma |
|
Neuroectodermal Tumors Neoplasms Neoplasms by Histologic Type Neoplasms, Germ Cell and Embryonal Neoplasms, Nerve Tissue |
Glioma Neoplasms, Neuroepithelial Ependymoma Neoplasms, Glandular and Epithelial |